home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605d.zip
/
M9651068.TXT
< prev
next >
Wrap
Text File
|
1996-03-30
|
2KB
|
32 lines
Document 1068
DOCN M9651068
TI A novel adjuvant for use with a blood-stage malaria vaccine.
DT 9505
AU de Souza JB; Playfair JH; University College London Medical School,
Department of; Immunology, UK.
SO Vaccine. 1995 Oct;13(14):1316-9. Unique Identifier : AIDSLINE
MED/96155139
AB An effective vaccine delivery system has been developed for vaccination
against a blood-stage malaria infection in mice. Subcutaneous
vaccination with a semi-purified asexual blood-stage malaria antigen
combined with an adjuvant formulation containing squalane, Tween 80 and
pluronic L121 (AF) protected mice infected with a lethal P. yoelii
infection against death and greatly reduced the severity and duration of
parasitaemia. The adjuvant and the route of immunization are both
clinically acceptable, thereby making this an attractive delivery system
for a human malaria vaccine. Protective immunity appeared to be
associated with an enhancement of both Th1 and Th2 subset cytokines.
DE Adjuvants, Immunologic/*THERAPEUTIC USE Animal Antibodies,
Protozoan/BIOSYNTHESIS Antigens, Protozoan/IMMUNOLOGY CD8-Positive
T-Lymphocytes/IMMUNOLOGY Female Injections, Subcutaneous Interferon
Type II/METABOLISM Interleukin-4/METABOLISM
Malaria/BLOOD/IMMUNOLOGY/*PREVENTION & CONTROL Malaria
Vaccines/*THERAPEUTIC USE Male Mice Mice, Inbred BALB C Mice, Inbred
C57BL Plasmodium yoelii/*IMMUNOLOGY Saponins/IMMUNOLOGY/THERAPEUTIC
USE Spleen/METABOLISM T-Lymphocytes, Cytotoxic/DRUG EFFECTS/IMMUNOLOGY
Th1 Cells/IMMUNOLOGY Th2 Cells/IMMUNOLOGY JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).